文献速递神经肿瘤神经重症

腺病毒介导CD40L动员CD4 T细胞治疗脑干肿瘤

Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors.
PubMed 文献 · Neuro Oncol · 2020-01-01

本研究在免疫活性小鼠脑干胶质瘤模型中验证瘤内注射表达CD40L的腺病毒可诱导免疫介导的肿瘤清除,CD4+ T细胞为关键效应细胞;但直接注射Ad-CD40L在已建立肿瘤中虽改善生存并获部分完全治愈,却伴随急性神经炎症毒性。构建复制严格限制于肿瘤细胞的rAd-Δ24-CD40L后,联合全身阻断IL-6和IL-1β可实现显著数量治愈且毒性可控。

要点

  • Ad-CD40L诱导脑干胶质瘤完全排斥依赖CD4+ T细胞。
  • 直接瘤内注射Ad-CD40L可改善生存但有急性神经炎症毒性。
  • rAd-Δ24-CD40L联合IL-6/IL-1β阻断实现可控毒性下显著治愈。

核心结论

  • 病毒介导的CD40L递送有望有效治疗弥漫性中线胶质瘤,且不必然伴随神经炎症相关毒性。

研究设计与样本

  • 在免疫活性小鼠脑干同基因胶质瘤模型中治疗Ad-CD40L并评估生存、毒性和免疫特征。
  • 在人类患者来源的弥漫性中线胶质瘤和免疫活性模型中测试复制严格限制于肿瘤细胞的rAd-Δ24-CD40L。

主要发现

  • 预感染限制Ad-CD40L表达于脑干胶质瘤可诱导完全排斥并伴免疫细胞浸润,CD4+ T细胞对治疗至关重要。
  • 直接瘤内注射Ad-CD40L至已建立脑干肿瘤改善生存并诱导部分完全治愈,但伴一些急性毒性。
  • RNA测序显示Ad-CD40L治疗诱导与IL-6、IL-1β和TNFα相关的神经炎症免疫反应。
  • 瘤内注射rAd-Δ24-CD40L联合全身阻断IL-6和IL-1β产生显著数量治愈且毒性易于管理。

临床怎么用

  • rAd-Δ24-CD40L联合IL-6和IL-1β全身阻断可能作为弥漫性中线胶质瘤的候选治疗策略,需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse midline glioma, formerly DIPG (diffuse intrinsic pontine glioma), is the deadliest pediatric brainstem tumor with median survival of less than one year. Here, we investigated (i) whether direct delivery of adenovirus-expressing cluster of differentiation (CD)40 ligand (Ad-CD40L) to brainstem tumors would induce immune-mediated tumor clearance and (ii) if so, whether therapy would be associated with a manageable toxicity due to immune-mediated inflammation in the brainstem. METHODS: Syngeneic gliomas in the brainstems of immunocompetent mice were treated with Ad-CD40L and survival, toxicity, and immune profiles determined. A clinically translatable vector, whose replication would be tightly restricted to tumor cells, rAd-Δ24-CD40L, was tested in human patient-derived diffuse midline gliomas and immunocompetent models. RESULTS: Expression of Ad-CD40L restricted to brainstem gliomas by pre-infection induced complete rejection, associated with immune cell infiltration, of which CD4+ T cells were critical for therapy. Direct intratumoral injection of Ad-CD40L into established brainstem tumors improved survival and induced some complete cures but with some acute toxicity. RNA-sequencing analysis showed that Ad-CD40L therapy induced neuroinflammatory immune responses associated with interleukin (IL)-6, IL-1β, and tumor necrosis factor α. Therefore, to generate a vector whose replication, and transgene expression, would be tightly restricted to tumor cells, we constructed rAd-Δ24-CD40L, the backbone of which has already entered clinical trials for diffuse midline gliomas. Direct intratumoral injection of rAd-Δ24-CD40L, with systemic blockade of IL-6 and IL-1β, generated significant numbers of cures with readily manageable toxicity. CONCLUSIONS: Virus-mediated delivery of CD40L has the potential to be effective in treating diffuse midline gliomas without obligatory neuroinflammation-associated toxicity.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Wongthida P, Schuelke MR, Driscoll CB, et al. Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors. Neuro Oncol. 2020. PMID: 32459315. doi:10.1093/neuonc/noaa126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。